15:49 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; SNPs; tissue markers Tumor expression levels of any one of 32 genes could predict survival in estrogen receptor-positive breast cancer. The protocol uses Capture Hi-C -- a method that maps transcriptional start sites...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Company News

Cytokinetics, GlaxoSmithKline deal

Cytokinetics and GlaxoSmithKline agreed to terminate a 2001 cancer deal, including returning rights to the biotech for GSK-923295. GSK will complete an ongoing Phase I trial of the small molecule centromere-associated protein E (CENPE)...
01:31 , Dec 10, 2009 |  BC Extra  |  Company News

Cytokinetics, GSK end cancer deal

Cytokinetics Inc. (NASDAQ:CYTK) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to terminate a 2001 cancer deal, including returning rights to the biotech for GSK- 923295. GSK will complete an ongoing Phase I trial of the small...
07:00 , Jun 1, 2009 |  BioCentury  |  Finance

Ebb & Flow

On its face, the deal to take out CuraGen Corp. (NASDAQ:CRGN) is returning about $0.18 for every dollar the genomics-based oncology company has raised since it went public. But the $94.5 million all-stock offer announced...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Company News

Cytokinetics, GlaxoSmithKline deal

GlaxoSmithKline will not exercise its option to license ispinesib and SB-743921 from Cytokinetics under a 2001 deal. GSK said the decision not to license the kinesin spindle protein ( KSP) inhibitors was due to...
02:04 , Dec 24, 2008 |  BC Extra  |  Company News

GSK passes on Cytokinetics options

GlaxoSmithKline (LSE:GSK;NYSE:GSK) said it will not exercise its option to license ispinesib and SB-743921 from Cytokinetics (NASDAQ:CYTK) under a 2001 deal. GSK said the decision not to license the kinesin spindle protein ( KSP) inhibitors...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

Cytokinetics, GlaxoSmithKline preclinical data

In mouse xenograft models of advanced colon cancer, animals receiving 125 mg/kg of GSK-923295 had a 6% decrease in tumor volume during the first treatment cycle while those receiving 62.5 mg/kg had a 7% increase....
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

GSK-923295: Phase I data

Additional preliminary data from an ongoing, dose-escalation Phase I trial in 11 patients with refractory advanced solid tumors showed that 1 patient with hepatoma experienced 6 months of stable disease, while 1 patient with pancreatic...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

Cytokinetics cancer, cardiovascular news

Cytokinetics restructured and reduced headcount by 45 (29%) to 111. The cuts occurred in G&A and early cancer research. Cytokinetics will discontinue its early stage cancer research program to focus on its preclinical muscle biology...
07:00 , Sep 22, 2008 |  BioCentury  |  Strategy

Leaving cancer behind

Faced with a decision about how best to utilize its platform technology targeting the cytoskeleton, Cytokinetics Inc. initially chose cancer as the path of least resistance for attracting investors and partners. Ten years later and...